Sirukumab (Janssen/GSK) to enter Phase III for RA - 24-Aug-2012

Janssen Biologics (Ireland) and GSK entered into a co-development and co-commercialisation license agreement with respect to sirukumab (CNTO 136),a human anti-interleukin (IL)-6 monoclonal antibody for Rheumatoid Arthritis.

Two studies comprise the Phase III program and are : SIRROUND-T, A multicentre, randomised, double-blind, placebo-controlled, parallel group study of sirukumab administered subcutaneously in subjects with active RA despite anti-tumor necrosis factor (TNF)-alpha therapy and SIRROUND-D, A multicentre, randomised, double-blind, placebo-controlled, parallel group study of sirukumab administered subcutaneously in subjects with active RA despite disease modifying anti-rheumatic drug (DMARD) therapy.